**Summary**
Novacyt S.A., an international molecular diagnostics company, released its full-year trading update for 2025, highlighting financial and commercial progress. Key points include
1. **Financial Performance**
Group revenue for FY 2025 is expected at £20.0m, in line with market expectations of £19.8m, representing a 4% growth (5% on a constant currency basis).
Clinical segment sales grew by 3% to £13.8m, driven by a new strategic customer in the APAC region and strong NIPT technology sales (+10%).
Instrumentation segment saw 25% growth to £2.5m, led by the successful launch of the LightBench® Discover instrument.
RUO segment declined by 10% to £3.7m due to reduced Primerdesign product sales.
APAC and Americas regions delivered growth of 10% and 8%, respectively.
Cash position remained strong at £19.2m, with the Group remaining debt-free.
2. **Commercial Highlights**
The LightBench® Discover instrument, launched in July 2025, has been successfully placed in 10 labs, with a robust pipeline for 2026.
The Primerdesign exsig® Mag RapidBead Pro Extraction Kit was launched in November 2025, offering superior DNA/RNA purification performance.
Beta testing for Yourgenes Insight DPYD assay is underway, with a product launch expected in H1 2026.
3. **Outlook**
The Group expects to report full-year results in April 2026.
CEO Lyn Rees emphasized the successful delivery of revenue growth, sequential half-year growth, and a strong foundation for future innovation.
Novacyt remains focused on driving innovation and executing its strategic plans across its Clinical, Instrumentation, and RUO segments.